In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vascular Therapeutics Inc.

Latest From Vascular Therapeutics Inc.

Vulnerable Plaque: Medical Device's New Biological Frontier

As interest in vulnerable plaque heats up, medical device companies hope to capitalize on their earl y lead. But as vulnerable plaque shifts therapies from structural to biological, that lead many not last long. The second of a two-part series.
Medical Device Platform Technologies

The Unstable State of Plaque Detection

Recent research points to unstable, rather than stenotic plaque, as a major cause of heart attacks. Cardiologists, as much as entrepreneurs and large companies, are therefore driving the creation of new cardiac detection platforms based on characterizing arterial plaque in order to identify patients that are unaware that they are at risk of suffering a myocardial infarction. First-generation detection tools are well along in development, but the scientific understanding about plaque is evolving so rapidly, technologies may be obsolete by the time they are ready for commercialization. Finally, looking for heart attack risk in symptomless patients means screening apparently healthy patients based on risk factors. Clinicians aren't yet prepared for the treatment implications and payers aren't ready for the economic burden of widespread screening, and this presents one of the greatest challenges for companies introducing new plaque detection technologies.
Medical Device Strategy

Biotechnology North of the Border

A venture-backed Canadian biotechnology industry is in its infancy, but faced with hostile capital markets, start-ups need clear exit plans. Consolidation's already started.
BioPharmaceutical Business Strategies

Vascular Therapeutics Inc.

Vascular Therapeutics is developing drugs to treat clotting disorders at the molecular level.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Vascular Therapeutics Inc.
  • Senior Management
  • Jim Allen, PhD, Pres. & CEO
    Paul Balsara, VP, Fin. & Admin. & CFO
  • Contact Info
  • Vascular Therapeutics Inc.
    Phone: (650) 903-5979
    700 East El Camino Real
    Suite 130
    Mountain View, CA 94040
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register